Immunome Inc. (IMNM): Shareholders' Equity
$634.34M
As of 2025-12-31
$525.08M
As of 2026-06-30
+236.5%
3-year compound annual growth
+72.7%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $634.34M | +250.1% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $181.16M | +51.1% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $119.88M | +619.9% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $16.65M | -65.4% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $48.19M | +16.5% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $41.34M | n/m | 2022-03-28, Balance as of period end |
| 2019-12-31 | -$35.63M | n/a | 2021-03-25, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Immunome Inc. (IMNM) | 2025-12-31 | $634.34M | +250.1% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $136.31M | +159.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $130.66M | +91.5% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $581.76M | -22.9% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $51.44M | -67.9% |
| Adagene Inc. (ADAG) | 2025-12-31 | $35.35M | -30.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $26.50M | -53.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $103.08M | -33.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
Compare IMNM, WHWK, OVID, XENE side by side · Screen every company in Pharmaceutical Preparations ↗